towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma towards improved death receptor targeted therapy for ... - TI Pharma
Chapter 7 Accumulation of thymidine‐derived sugars in thymidine phosphorylase overexpressing cells. Irene V. Bijnsdorp, Kaamar Azijli, Erwin E. Jansen, Mirjam M. Wamelink, Carel Jakobs, Eduard A. Struys, Masakazu Fukushima, Frank A.E. Kruyt, Godefridus J. Peters Biochemical Pharmacology, 2010; 80(6):786‐92
Chapter 7 ABSTRACT Thymidine phosphorylase (TP) is often overexpressed in cancer and potentially plays a role in the stimulation of angiogenesis. The exact mechanism of angiogenesis induction is unclear, but is postulated to be related to thymidine‐derived sugars. TP catalyzes the conversion of thymidine (TdR) to thymine and deoxyribose‐1‐phosphate (dR‐1‐P), which can be converted to dR‐5‐P, glyceraldehyde‐3‐phosphate (G3P) or deoxyribose (dR). However, it is unclear which sugar accumulates in this reaction. Therefore, in the TP overexpressing Colo320 TP1 and RT112/TP cells we determined by LC‐MS/MS which sugars accumulated, their subcellular localization (using 3 H‐TdR) and whether dR was secreted from the cells. In both TP‐overexpressing cell lines, dR‐1‐P and dR‐5‐P accumulated intracellularly at high levels and dR was secreted extensively by the cells. A specific inhibitor of TP completely blocked TdR conversion, and thus no sugars were formed. To examine whether these sugars may be used for the production of angiogenic factors or other products, we determined with 3 H‐TdR in which subcellular location these sugars accumulated. TdR‐derived sugars accumulated in the cytoskeleton and to some extent in the cell membrane, while incorporation into the DNA was responsible for trapping in the nucleus. In conclusion, various metabolic routes were entered, of which the TdR‐derived sugars accumulated in the cytoskeleton and membrane. Future studies should focus on which exact metabolic pathway is involved in the induction of angiogenesis. Key Words: Thymidine phosphorylase, angiogenesis, deoxyribose, thymidine phosphorylase inhibitor ‐ 118 ‐
- Page 67 and 68: Chapter 4 RESULTS TRAIL induces a s
- Page 69 and 70: Chapter 4 vehicle control or with 5
- Page 71 and 72: Chapter 4 Non‐canonical TRAIL res
- Page 73 and 74: Chapter 4 A549‐shRIP1 cells clear
- Page 75 and 76: Chapter 4 Figure 7. Inhibition of S
- Page 77 and 78: Chapter 4 DISCUSSION The TRAIL rece
- Page 79 and 80: Chapter 4 Src‐independent mechani
- Page 81 and 82: Chapter 4 variants. Cell Death Dis
- Page 83 and 84: Chapter 4 ‐ 82 ‐
- Page 85 and 86: Chapter 5 ABSTRACT TRAIL is an inte
- Page 87 and 88: Chapter 5 targets and subsequent pr
- Page 89 and 90: Chapter 5 RESULTS Synergistic activ
- Page 91 and 92: Chapter 5 ng/ml TRAIL (Fig. 3B). Ap
- Page 93 and 94: Chapter 5 by sub‐G1 levels in the
- Page 95 and 96: Chapter 5 DISCUSSION In the present
- Page 97 and 98: Chapter 5 Reference List 1. Jemal A
- Page 99 and 100: Chapter 5 ‐ 98 ‐
- Page 101 and 102: Chapter 6 ABSTRACT TRAIL is a tumor
- Page 103 and 104: Chapter 6 various stress stimuli [1
- Page 105 and 106: Chapter 6 Subsequently, the membran
- Page 107 and 108: Chapter 6 B H460 A549 Figure 1. Rep
- Page 109 and 110: Chapter 6 TRAIL‐dependent cell de
- Page 111 and 112: Chapter 6 B H460 A549 C Figure 4 (c
- Page 113 and 114: Chapter 6 Figure 5 (continued). Mec
- Page 115 and 116: Chapter 6 regulation and checkpoint
- Page 117: Chapter 6 mechanism of immune evasi
- Page 121 and 122: Chapter 7 Figure 1. Schematic overv
- Page 123 and 124: Chapter 7 that was measured before
- Page 125 and 126: Chapter 7 RESULTS TdR conversion to
- Page 127 and 128: Chapter 7 dR is secreted from the c
- Page 129 and 130: Chapter 7 Figure 4. Accumulation of
- Page 131 and 132: Chapter 7 angiogenic properties. Ho
- Page 133 and 134: Chapter 7 activity of enzymes. Natu
- Page 135 and 136: Chapter 7 ‐ 134 ‐
- Page 137 and 138: Chapter 8 SUMMARIZING DISCUSSION AN
- Page 139 and 140: Chapter 8 Recently, various differe
- Page 141 and 142: Chapter 8 in phase II clinical tria
- Page 143 and 144: Chapter 8 Reference List 1. Herbst
- Page 145 and 146: Chapter 8 ‐ 144 ‐
- Page 147 and 148: Chapter 9 NEDERLANDSE SAMENVATTING
- Page 149 and 150: Chapter 9 waargenomen. Het gebruik
- Page 151 and 152: Chapter 9 CONCLUSIE Het activeren v
- Page 153 and 154: zelfs na werktijden (lees 23:45) ko
- Page 155 and 156: Verder wil ik ook dr. Eric Ronken b
Chapter 7<br />
Accumulation of thymidine‐derived sugars in<br />
thymidine phosphorylase overexpressing cells.<br />
Irene V. Bijnsdorp, Kaamar Azijli, Erwin E. Jansen, Mirjam M. Wamelink,<br />
Carel Jakobs, Eduard A. Struys, Masakazu Fukushima, Frank A.E. Kruyt,<br />
Godefridus J. Peters<br />
Biochemical <strong>Pharma</strong>cology, 2010; 80(6):786‐92